NCT03103256View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Hypertension and Hyperlipidemia
Interventions
DRUG

YHP1701

PO, Once daily (QD), 8 weeks

DRUG

YHR1703

PO, Once daily (QD), 8 weeks

DRUG

YHR1704

PO, Once daily (QD), 8 weeks

Trial Locations (1)

Unknown

Seoul Medical Center, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03103256 - Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 | Biotech Hunter | Biotech Hunter